IAC Express 2009 |
Issue number 829: October 26, 2009 |
|
Please click here to subscribe to IAC Express
as well as other FREE IAC periodicals. |
|
Contents
of this Issue
Select a title to jump to the article. |
- CDC posts
the provisional recommendations for use of MMRV vaccine on its ACIP web
section
- FDA
approves seasonal influenza vaccine Fluarix for use in children and teens
ages 3 to 17 years
- President
Obama signs emergency declaration for H1N1 influenza
-
Immunization Techniques video (DVD or VHS) offers a great way to give
staff high-quality vaccination instruction
- CDC's
H1N1 information includes H1N1 billing Q&As, 10 most frequently asked H1N1
questions, and much more
- Set for
Nov. 12, CDC's "Current Issues in Immunization" Net Conference will cover
new HPV recommendations
- Wired
magazine profiles Dr. Paul A. Offit in the context of his work to dispel
autism myths
- Seasonal
influenza vaccine pocket guides--FREE!--from the National Influenza
Vaccine Summit
- IAC's
Video of the Week features a 60 Minutes report on H1N1 influenza
- IAC
updates a print Q&A that answers the public's questions about seasonal
influenza
- Keep
vaccinating against seasonal influenza!
- MMWR
article reports substantial decrease in U.S. rotavirus disease since
vaccine introduction in 2006
- VISs for
seasonal influenza vaccines now available in Bengali, Haitian Creole, and
Urdu
- Check
out the Childhood Influenza Immunization Coalition's new videos, PSAs, and
survey results
- A new
Vaccine Adverse Event Reporting System website has been launched
- "State
of the World's Vaccines and Immunization" focuses on major developments
since 2000
- MMWR
article covers introduction and transmission of H1N1 influenza virus in
Kenya in 2009
- MMWR
article discusses recent progress made toward eradicating polio in Nigeria
- Phacilitate's North
American Vaccine Forum scheduled for January 25-27 in Washington, DC
|
|
Abbreviations |
|
AAFP, American Academy of Family Physicians; AAP,
American Academy of Pediatrics; ACIP, Advisory Committee on Immunization
Practices; AMA, American Medical Association; CDC, Centers for Disease
Control and Prevention; FDA, Food and Drug Administration; IAC, Immunization
Action Coalition; MMWR, Morbidity and Mortality Weekly Report; NCIRD,
National Center for Immunization and Respiratory Diseases; NIVS, National
Influenza Vaccine Summit; VIS, Vaccine Information Statement; VPD,
vaccine-preventable disease; WHO, World Health Organization. |
|
Issue 829: October 26, 2009 |
|
|
1. |
CDC posts the
provisional recommendations for use of MMRV vaccine on its ACIP web section
On October 20, CDC posted provisional
recommendations for
use of measles, mumps, rubella, and varicella (MMRV) vaccine
on the ACIP web section. Provisional recommendations are
those ACIP has voted on but that are not yet approved by CDC
or the Department of Health and Human Services and have not
yet been published in MMWR. The MMRV provisional
recommendations are reprinted below in their entirety.
ACIP PROVISIONAL RECOMMENDATIONS FOR USE OF MEASLES, MUMPS,
RUBELLA AND VARICELLA (MMRV) VACCINE
Date of ACIP vote: June 25, 2009
Date of posting of provisional recommendations: October 20,
2009
On June 25, 2009, ACIP voted on updated recommendations for
use of MMRV vaccine and approved other MMRV vaccine-related
guidance. The updated provisional recommendations for use of
MMRV vaccine and CDC implementation guidance are listed
below.
DOSE 1 AT AGES 12 THROUGH 47* MONTHS
For the first dose of measles, mumps, rubella, and varicella
vaccines at ages 12 through 47 months, either MMR and
varicella vaccines or MMRV vaccine can be used. Providers
who are considering administering MMRV vaccine should
discuss the benefits and risks of both vaccination options
with the parents or caregivers. Compared with use of MMR and
varicella vaccines at the same visit, use of MMRV vaccine
results in one fewer injection but is associated with a
higher risk for fever and febrile seizures 5 through 12 days
after the first dose among children aged 12 through 23
months* (about one extra febrile seizure for every 2,300-2,600 MMRV vaccine doses). Use of MMR and varicella vaccines
avoids this increased risk for fever and febrile seizures
following MMRV vaccine. Providers who face barriers to
clearly communicating these benefits and risks for any
reason (e.g., language barriers) should administer MMR and
varicella vaccines.
DOSE 1 AT AGES 48 MONTHS AND OLDER AND DOSE 2 AT ANY AGE
For the first dose of measles, mumps, rubella, and varicella
vaccines at ages 48 months and older and for dose 2 at any
age (15 months through 12 years), use of MMRV vaccine
generally is preferred over separate injections of its
equivalent component vaccines (i.e., MMR and varicella
vaccines). Considerations should include provider
assessment**, patient preference, and the potential for
adverse events.
Of note, the routinely recommended ages for measles, mumps,
rubella and varicella vaccination continue to be 12 through
15 months of age for dose 1 and 4 through 6 years of age for
dose 2.
OTHER MMRV VACCINE-RELATED GUIDANCE
New Precaution for MMRV Vaccine Use:
A personal or family (i.e., sibling, parent) history of
seizures is a precaution for MMRV vaccination. Studies
suggest that children who have a personal or family history
of febrile seizures or family history of epilepsy are at
increased risk for febrile seizures compared with children
who do not have such histories. Children with a personal or
family history of seizures generally should be vaccinated
with MMR and varicella vaccines because the risks of using
MMRV vaccine in this group of children generally outweigh
the benefit of MMRV vaccine.
CDC has developed materials to help with the implementation
of the updated recommendations for use of MMRV vaccine:
www.cdc.gov/vaccines/vpd-vac/combo-vaccines/mmrv/vacopt.htm* The 47 month cut-off was chosen on the basis of the
epidemiology of febrile seizures: first febrile seizures are
uncommon after age 4 years; approximately 94% of febrile
seizures occur in children aged less than 4 years.
** Provider assessment should include the number of
injections, vaccine availability, likelihood of improved
coverage, likelihood of patient return, and storage and cost
consideration.
This document can be found on the CDC website at:
www.cdc.gov/vaccines/recs/provisional
To access the MMRV provisional recommendations, go to:
http://www.cdc.gov/vaccines/recs/provisional/downloads/mmrv-oct2009-508.pdf
All provisional ACIP recommendations can be found at
http://www.cdc.gov/vaccines/recs/provisional
To access all final ACIP recommendations, go to:
http://www.immunize.org/acip IAC's ACIP web section allows
visitors to sort documents by date, vaccine, or topic.
Bookmark this link for easy access to all provisional and
final ACIP recommendations.
Back to top |
|
|
2. |
FDA approves seasonal influenza vaccine Fluarix for use in children and teens
ages 3 to 17 years
On October 19, FDA issued a press release, "FDA
Approves
Seasonal Influenza vaccine Fluarix for Pediatric Use."
Fluarix is manufactured by GlaxoSmithKline Biologicals,
Dresden, Germany. Portions of the press release are
reprinted below. Links to the approval letter and package
insert are given at the end of this IAC Express article.
The U.S. Food and Drug Administration today approved use of
the seasonal influenza vaccine Fluarix for children ages 3
years to 17 years. Previously, this vaccine, which contains
inactivated (killed) influenza A and B viruses, had been
approved for use in adults, ages 18 years and older.
The safety and effectiveness of Fluarix for use in children
ages 3 years and older is documented by a U.S. study
comparing 2,115 children who received Fluarix with 1,210
children who received Fluzone, a different influenza vaccine
already licensed by the FDA for use in children ages 6
months and older. Study results showed that children 3 years
and older vaccinated with Fluarix and Fluzone produced
similar amounts of antibodies in the blood at levels
considered likely to be protective against seasonal
influenza.
Fluarix is a seasonal influenza vaccine not intended to
protect against the 2009 H1N1 influenza virus. . . .
To access the complete press release, go to:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187156.htm
To access the approval letter, go to:
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm187207.htm
To access the package insert, click
here.
Back to top |
|
|
3. |
President Obama signs emergency declaration for H1N1 influenza
On October 24, President Obama signed an
emergency
declaration for H1N1 influenza. The proclamation enhances
the ability of our nation's medical treatment facilities to
handle a surge in H1N1 patients by allowing, as needed, the
waiver of certain standard federal requirements on a case-by-case basis.
To access details about the declaration, go to:
http://www.flu.gov/professional/federal/h1n1emergency10242009.html
Back to top |
|
|
4. |
Immunization Techniques video (DVD or VHS) offers a great way to give staff
high-quality vaccination instruction
If your healthcare setting is vaccinating a lot
more people
than usual because of H1N1 influenza, this is a great time
for your staff to review the recommended immunization
techniques shown in the video Immunization Techniques: Safe,
Effective, Caring. This popular and highly lauded 35-minute
video offers healthcare providers a way to train their
staff--quickly, effectively, and affordably (only $10.50 for
each DVD or VHS ordered).
Developed in 2001 by the California Department of Health
Services Immunization Branch in collaboration with a team of
national experts, the video teaches best practices for
administering intramuscular (IM) and subcutaneous (SC)
vaccines to infants, children, and adults. PLEASE NOTE,
however, that because the video was released in 2001, it
does NOT provide instruction on administering the nasal-spray influenza vaccines or the oral rotavirus vaccines.
These vaccines were licensed after 2001.
Available in DVD and VHS formats, the video is designed for
use as a "hands-on" instructional program for new staff, as
well as a refresher course for experienced healthcare
professionals. It discusses the following:
-
Anatomic sites
-
Choice of needle size
-
Vaccines and routes of administration
-
Demonstrations of infants, toddlers, kindergartners, and
adults being vaccinated
-
How to "draw up" doses of vaccine
TO ORDER OR FOR ADDITIONAL INFORMATION. The cost is $10.50
per copy of the DVD or VHS.
For additional information about the DVD, or to order online
or to download an order form, visit
http://www.immunize.org/shop/toolkit_iztechdvd.asp
For additional information about the VHS, or to order online
or to download an order form, visit
http://www.immunize.org/shop/toolkit_iztechvhs.asp
Back to top |
|
|
5. |
CDC's H1N1 information includes H1N1 billing Q&As, 10 most frequently asked
H1N1 questions, and much more
CDC recently added or updated the following H1N1
influenza
information for healthcare professionals.
H1N1 Vaccine Administration Billing Q&As
http://www.cdc.gov/h1n1flu/vaccination/statelocal/vaccing_billing_qa.htm
Top 10 Frequently Asked Questions on Use of Influenza
A(H1N1) 2009 Monovalent Vaccines (2009 H1N1 Vaccines):
Practical Considerations for Immunization Programs and
Providers
http://www.cdc.gov/H1N1flu/vaccination/top10_faq.htm
H1N1 Vaccine Allocation and Distribution Q&A
http://www.cdc.gov/H1N1flu/vaccination/statelocal/centralized_distribution_qa.htm
Updated Interim Recommendations--HIV-Infected Adults and
Adolescents: Considerations for Clinicians Regarding 2009
H1N1 Influenza
http://www.cdc.gov/h1n1flu/guidance_HIV.htm
Antiviral Safety Information Web Page
http://www.cdc.gov/H1N1flu/antivirals/safety_info.htm
Health Requirements and Recommendations for Travel to Saudi
Arabia during the 2009 Hajj: Information for U.S. Travelers
http://wwwnc.cdc.gov/travel/content/id/2434.aspx
Emergency Use Authorization of N95 Respirators
http://www.cdc.gov/h1n1flu/eua/n95.htm
CDC Health Alert Network (HAN) Info Service Message:
Recommendations for Early Empiric Antiviral Treatment in
Persons with Suspected Influenza who are at Increased Risk
of Developing Severe Disease
http://www.cdc.gov/H1N1flu/HAN/101909.htm
Podcast: Antiviral Drugs for the 2009-2010 Influenza Season
http://www2c.cdc.gov/podcasts/player.asp?f=175219#
Planning Guide for Vaccinating Pediatric Patients against
2009 H1N1 Influenza in Primary Healthcare Settings
http://www.cdc.gov/h1n1flu/vaccination/pediatricpatients.htm
2009-2010 Influenza Triage Algorithm for Children (18 years
or Younger) with Influenza-Like Illness
http://www.cdc.gov/h1n1flu/clinicians/pdf/childalgorithm.pdf
Recommendations for Use of Antiviral Medications for the
Management of Influenza in Children and Adolescent for the
2009-2010 Season--Pediatric Supplement for Health Care
Providers
http://www.cdc.gov/h1n1flu/recommendations_pediatric_supplement.htm
Updated Interim Recommendations for the Use of Antiviral
Medications in the Treatment and Prevention of Influenza for
the 2009-2010 Season
http://www.cdc.gov/h1n1flu/recommendations.htm
2009 H1N1 Flu (referred to as "swine flu" early on) and
Seasonal Flu Information for Rheumatology Health
Professionals
http://www.cdc.gov/h1n1flu/arthritis_clinicians.htm
CDC's H1N1 Flu web section contains hundreds of documents
for healthcare professionals and the public. To access the
web section's home page, go to: http://www.cdc.gov/h1n1flu
To make it easy for you to keep up to date with
developments, IAC has gathered important information related
to H1N1 influenza into a single web section. To access this
resource, go to:
http://www.immunize.org/h1n1
Back to top |
|
|
6. |
Set for Nov. 12, CDC's "Current Issues in Immunization" Net Conference will
cover new HPV recommendations
The next NCIRD live Net Conference will cover new
recommendations for human papillomavirus (HPV) vaccine. An
additional topic will be discussed, but it has not yet been
determined. The Net Conference is scheduled from noon to 1PM
ET on November 12. Dr. Lauri Markowitz will speak on HPV;
Dr. Andrew Kroger will moderate. Participation in the Q&A
section of the program is available by phone and Internet.
For additional information, go to:
http://www.cdc.gov/vaccines/ed/ciinc
This is a limited-entry event. Registration will close on
November 10 or when the course is full. To register, go to:
http://www2.cdc.gov/vaccines/ed/ciinc
Back to top |
|
|
7. |
Wired magazine profiles Dr. Paul A. Offit in the context of his work to
dispel autism myths
On October 19, the website of Wired magazine
posted "An
Epidemic of Fear: How Panicked Parents Skipping Shots
Endangers Us All." Written by Amy Wallace, the article
profiles Dr. Paul A. Offit in the context of his work to
dispel the myth that vaccines cause autism. A science
advocate, Dr. Offit is chief of Infectious Diseases and
director of the Vaccine Education Center at Children's
Hospital of Philadelphia. He is also a co-inventor of the
rotavirus vaccine RotaTeq.
To access the article "An Epidemic of Fear: How Panicked
Parents Skipping Shots Endangers Us All," go to:
http://www.wired.com/magazine/2009/10/ff_waronscience
Earlier this month, the American Academy of Pediatrics
presented Dr. Offit with its President's Certificate for
Outstanding Service in recognition of his ongoing commitment
to promote immunization.
To access the AAP press release about the award, go to:
http://www.aap.org/advocacy/releases/nce09outstandingaward.htm
Back to top |
|
|
8. |
Seasonal influenza vaccine pocket guides--FREE!--from the National Influenza
Vaccine Summit
With vaccination against 2009 H1N1 influenza
underway, it is
important to remember that seasonal influenza vaccination
efforts must continue. To aid in these efforts, the
Immunization Action Coalition is inviting IAC Express
readers to place orders now for the National Influenza
Vaccine Summit's 2009-10 Seasonal Influenza Vaccination
Pocket Information Guides. They're free!
These laminated, 3.75 x 6.75-inch, 2-color cards serve as a
convenient reference for front-line healthcare professionals
who vaccinate patients. The cards provide the following
information:
-
Indications, contraindications, and precautions for the
injectable and intranasal seasonal influenza vaccines
-
Populations targeted for seasonal influenza vaccination
-
Dosage and route of administration for all the various
seasonal influenza vaccine products
-
Talking points for discussing seasonal influenza
vaccination with patients
See an image of the seasonal influenza vaccine pocket guide
at
http://www.preventinfluenza.org/fluguide/pocketguide_flu.pdf
These pocket guides also serve as a reminder to keep giving
seasonal influenza vaccine throughout the influenza season
(through the spring months).
The Summit is also pleased to be able to offer pocket guides
for the administration of pneumococcal polysaccharide
vaccine (PPSV). See an image of the PPSV pocket guide at
http://www.immunize.org/ppvguide/pocketguide.pdf
Each of these pocket guides is designed to be used by
healthcare professionals only; THEY ARE NOT PATIENT
HANDOUTS.
HOW TO ORDER
Each order must be for a minimum of 100 pocket guides. Place
your order at http://www.preventinfluenza.org/pocketguides
There is no cost for the pocket guides, shipping, or
handling within the U.S. Quantities are limited, so to avoid
disappointment, place your order today!
If you have questions, email admininfo@immunize.org
BACKGROUND
These pocket guides were developed by, and are being
provided under the sponsorship of the National Influenza
Vaccine Summit, http://www.preventinfluenza.org The Summit
brings together public and private stakeholders to
facilitate and promote influenza vaccination. The pocket
guides are also distributed by many major medical, nursing,
and pharmacist organizations, specialty societies, state
health departments, Indian Health Service Area facilities,
Quality Improvement Organizations, Visiting Nurse
Associations, community vaccinators, and many others.
Thanks for your dedication to immunization, and don't forget
to keep vaccinating against seasonal influenza through the
spring months!
Back to top |
|
|
9. |
IAC's Video of the Week features a 60 Minutes report on H1N1 influenza
IAC encourages IAC Express readers to watch a
9-minute video
of CBS correspondent Scott Pelley's report on the H1N1
influenza. The report, which aired on October 18, looks at
how H1N1 influenza is striking at young, healthy people and
presents information about the federal government's plans to
fight the H1N1 pandemic.
The video will be available on the home page of IAC's
website through November 1. To access it, go to:
http://www.immunize.org and click on the image under the
words Video of the Week. It may take a few moments for the
video to begin playing; please be patient!
Remember to bookmark IAC's home page to view a new video
every Monday. To view an IAC Video of the Week from the
past, go to the video archive at http://www.immunize.org/votw
Back to top |
|
|
10. |
IAC updates a print Q&A that answers the public's questions about seasonal
influenza
IAC recently revised its Q&A patient-education
print piece
"Seasonal Influenza: Questions and Answers." The word
"seasonal" was added to the title and throughout the piece,
and very small revisions were made to incorporate changes in
vaccine recommendations.
The revised piece is a ready-to-print version of some of the
CDC-reviewed material located on IAC's Vaccine Information
website (www.vaccineinformation.org). The website is
intended for the public, health professionals, and the
media.
To access the revised ready-to-print (PDF) print piece
"Seasonal Influenza: Questions and Answers," go to:
http://www.immunize.org/catg.d/p4208.pdf
For a web-text (HTML) version of this and other fully
formatted documents, go to: http://www.vaccineinformation.org You will be taken to a
list of Q&As about vaccine-preventable diseases and the
vaccines that prevent them. Click on the disease(s) of
interest to you.
To access Q&As about other diseases and vaccines in ready-to-print (PDF) format, go to:
http://www.immunize.org/printmaterials/questions.asp
IAC's Print Materials web section offers healthcare
professionals and the public approximately 250 FREE English-language materials (many also available in translation),
which we encourage website users to print out, copy, and
distribute widely. To access all of IAC's free print
materials, go to:
http://www.immunize.org/printmaterials
Back to top |
|
|
11. |
Keep vaccinating against seasonal influenza!
If you're wondering if you should continue to
vaccinate
against seasonal influenza when H1N1 influenza vaccine
becomes available, the answer is YES! The 2009 H1N1
influenza vaccine will not protect people against seasonal
influenza, and seasonal influenza vaccine will not protect
against H1N1 influenza.
Unfortunately, some healthcare facilities are having
difficulty finding available seasonal influenza vaccine to
purchase. Be assured that though vaccine may be in temporary
short supply in some settings right now, supplies are
expected to catch up to demand soon.
To assist providers in finding seasonal influenza vaccine
available for purchase, the National Influenza Vaccine
Summit supports IVATS (Influenza Vaccine Availability
Tracking System). IVATS provides information about vaccine
manufacturers and distributors with vaccine available for
purchase. To access this information in Excel spreadsheet
format, go to:
http://www.preventinfluenza.org/ivats/ivats_09_10.xls
Many resources regarding influenza disease and vaccination
are available to healthcare professionals and the public.
Following is a list of some of them.
To access the National Influenza Vaccine Summit website, go
to:
http://www.preventinfluenza.org
To access IAC's Seasonal Influenza web section, go to:
http://www.immunize.org/influenza
To access IAC's H1N1 Influenza web section, go to:
http://www.immunize.org/h1n1
To access CDC's Seasonal Flu web section, go to:
http://www.cdc.gov/flu
To access CDC's Novel H1N1 Flu web section, go to:
http://www.cdc.gov/h1n1flu
To access IAC's print pieces related to influenza, including
screening questionnaires, patient education pieces, and
sample standing orders, go to:
http://www.immunize.org/printmaterials/dis_inf.asp
Back to top |
|
|
12. |
MMWR article reports substantial decrease in U.S. rotavirus disease since
vaccine introduction in 2006
CDC published "Reduction in Rotavirus After
Vaccine
Introduction--United States, 2000-2009" in the October 23
issue of MMWR. A summary made available to the press is
reprinted below in its entirety.
Rotavirus disease in U.S. children has decreased
substantially since the introduction of routine vaccination
of U.S. infants against rotavirus. Worldwide, rotavirus is
the leading cause of severe acute diarrhea in children aged
<5 years. In the United States, before introduction of a
rotavirus vaccine in 2006, rotavirus caused an estimated 20-60 deaths, 55,000-70,000 hospitalizations, 205,000-272,000
emergency department visits, and 410,000 outpatient visits
annually in children <5 years of age. CDC analyzed data from
a national network of sentinel laboratories which showed
that the 2007-08 and 2008-09 seasons were both shorter and
later than during pre-vaccine seasons in 2000-2006. Although
the 2008-09 season had slightly more positive rotavirus test
results than in 2007-08, the number of positive test results
for both seasons was substantially lower than during 2000-2006. Cases of rotavirus disease have decreased since
introduction of rotavirus vaccination, but continued
surveillance is needed to better characterize the impact of
rotavirus vaccine.
To access the full article in web-text (HTML) format, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5841a2.htm
To access a ready-to-print (PDF) version of this issue of
MMWR, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5841.pdf
To receive a FREE electronic subscription to MMWR (which
includes new ACIP recommendations), go to:
http://www.cdc.gov/mmwr/mmwrsubscribe.html
Back to top |
|
|
13. |
VISs for seasonal influenza vaccines now available in Bengali, Haitian
Creole, and Urdu
Dated 8/11/09, the interim VIS for seasonal
trivalent
inactivated influenza vaccine (TIV; injectable) and the VIS
for seasonal live attenuated influenza vaccine (LAIV; nasal
spray) are now available in Bengali, Haitian Creole, and
Urdu. IAC gratefully acknowledges the New York City
Department of Education and the New York City Department of
Health and Mental Hygiene for the translations.
INTERIM VIS FOR THE SEASONAL INJECTABLE INFLUENZA VACCINE
To access the Bengali version of the interim VIS for
seasonal injectable influenza vaccine, go to:
http://www.immunize.org/vis/be_flu.pdf
To access the Haitian Creole version of the interim VIS for
seasonal injectable influenza vaccine, go to:
http://www.immunize.org/vis/ha_flu06.pdf
To access the Urdu version of the interim VIS for seasonal
injectable influenza vaccine, go to:
http://www.immunize.org/vis/ur_flu.pdf
To access the English version of the interim VIS for
seasonal injectable influenza vaccine, go to:
http://www.immunize.org/vis/2flu.pdf
NOTE: The interim VIS for seasonal injectable influenza
vaccine comes in additional languages, including Spanish. To
access them, go to:
http://www.immunize.org/vis/vis_flu_inactive.asp Click on
the link to the pertinent language.
VIS FOR THE SEASONAL NASAL-SPRAY INFLUENZA VACCINE
To access the Bengali version of the VIS for seasonal nasal-spray influenza vaccine, go to:
http://www.immunize.org/vis/be_LAIV.pdf
To access the Haitian Creole version of the VIS for seasonal
nasal-spray influenza vaccine, go to:
http://www.immunize.org/vis/haliveflu06.pdf
To access the Urdu version of the VIS for seasonal nasal-spray influenza vaccine, go to:
http://www.immunize.org/vis/ur_LAIV.pdf
To access the English version of the VIS for seasonal nasal-spray influenza vaccine, go to:
http://www.immunize.org/vis/liveflu.pdf
NOTE: The VIS for seasonal nasal-spray influenza vaccine
comes in additional languages, including Spanish. To access
them, go to: http://www.immunize.org/vis/vis_flu_live.asp
Click on the link to the pertinent language.
For information about the use of VISs, and for VISs in more
than 35 languages, visit IAC's VIS web section at
http://www.immunize.org/vis
For general information about VISs from CDC's website go to:
http://www.cdc.gov/vaccines/pubs/vis
Back to top |
|
|
14. |
Check out the Childhood Influenza Immunization Coalition's new videos, PSAs,
and survey results
The website of Childhood Influenza
Immunization Coalition
(CIIC) was recently updated with new videos, public service
announcements (PSAs), and the results of a survey conducted
by the National Foundation for Infectious Diseases (NFID).
Details follow.
CIIC's new attention-grabbing online videos use humor to
help clear up some common misperceptions among parents about
influenza and the benefit of immunization for their
children. Titled "Flu Funnies," the videos are available at
http://www.preventchildhoodinfluenza.org/families/influenza_flu_funnies_videos.php
or http://www.youtube.com/user/NFIDVideos
Through brief vignettes about a family, CIIC's PSAs
illustrate the potentially devastating impact influenza has
on children and the importance of immunization. They are
available in English and Spanish; email CIIC@NFID.org to
access them, free of charge.
As part of a CIIC effort, NFID conducted a national survey
to better understand mothers' perceptions of seasonal
influenza immunization. In general, mothers view seasonal
influenza vaccine as safe and effective, yet misperceptions
still cause some to avoid this immunization for their
children. Read more at
www.PreventChildhoodInfluenza.org/survey
CIIC was established by NFID. Its members represent more
than 30 of the nation's leading public health, medical,
patient, and parent groups committed to protecting
children's health and encouraging wellness.
To access the CIIC website's homepage, go to:
http://www.preventchildhoodinfluenza.org
Back to top |
|
|
15. |
A
new Vaccine Adverse Event Reporting System website has been launched
A new website for the Vaccine Adverse Event
Reporting System
(VAERS) has been launched and is available at
http://www.vaers.hhs.gov VAERS is a national program co-managed by CDC and FDA to monitor the safety of all vaccines
licensed in the United States.
VAERS is a passive surveillance system that collects and
analyzes important information from reported adverse events
that occur after vaccination. The system relies on reports
from healthcare providers, vaccine manufacturers, and the
general public. You may report to VAERS electronically, by
mail, or fax. You can also search the VAERS database, via
the website, for information and summaries on particular
adverse events reported for specific vaccines. Please note
that VAERS cannot determine if an adverse event was caused
by a vaccine, but can help determine if further
investigations are needed.
In addition, VAERS print and web material are now available
on the CDC website at
http://www.cdc.gov/vaccinesafety/vaers/vaers_campaign.htm
Back to top |
|
|
16. |
"State of the World's Vaccines and Immunization" focuses on major
developments since 2000
On October 21, WHO's Department of Immunization,
Vaccines
and Biologicals (IVB) posted a summary of the content of the
recently released third edition of a report titled "State of
the World's Vaccines and Immunization." The report is a
collaboration among WHO, UNICEF, and the World Bank.
The IVB summary is reprinted below in its entirety. Links to
the recently released report and to a related WHO press
release and a related "CDC Feature" are given at the end of
this IAC Express article.
The "State of the World's Vaccines and Immunization" (third
edition) is a call to action to governments and donors to
sustain and increase funding for immunization in order to
build upon the progress made so far in meeting the global
goals. It focuses on the major developments in vaccines and
immunization since 2000.
Part 1 examines the impact of immunization on efforts to
meet the Millennium Development Goals, especially the goal
to reduce deaths among children under five. It looks at the
development and use of vaccines and at the safeguards that
have been put in place to ensure their safety, efficacy, and
quality. It sets out the progress and challenges in meeting
the immunization-related global goals. It discusses both the
cost of scaling up immunization coverage to meet these
goals, and efforts to ensure that the achievements are
sustainable in the long term. Finally, it looks beyond 2015
to likely changes in the immunization landscape.
Part 2 describes over 20 vaccine-preventable diseases and
reviews progress since 2000 in efforts to protect
populations against these diseases through the use of
vaccines.
To access the full report, as well as the report's executive
summary in several languages, go to:
http://www.who.int/immunization/sowvi/en
To access the WHO press release about the report, go to:
http://www.who.int/mediacentre/news/releases/2009/state_immunizaton_20091021/en
To access the "CDC Feature" on the report, go to:
http://www.cdc.gov/Features/GlobalImmunizations
Back to top |
|
|
17. |
MMWR article covers introduction and transmission of H1N1 influenza virus in
Kenya in 2009
CDC published "Introduction and Transmission of
2009
Pandemic Influenza A (H1N1) Virus--Kenya, June-July 2009" in
the October 23 issue of MMWR. A summary made available to
the press is reprinted below in its entirety.
Investigations into the initial cases of 2009 pandemic
influenza A (H1N1) showed that the infectiousness of the
pandemic influenza virus may be similar to that of seasonal
influenza, but more studies are needed to better understand
the infectiousness of the pandemic virus. Only one small
retrospective study has reported a 30 percent secondary
attack rate for laboratory-confirmed 2009 pandemic influenza
A (H1N1) among tourists to China. Investigations into the
initial cases of 2009 pandemic influenza A (H1N1) in Kenya
during June-July 2009 showed an overall laboratory-confirmed
secondary attack rate of 26 percent in households, which is
similar to rates reported previously for seasonal influenza.
However, additional studies are needed to better understand
the secondary attack rates for laboratory confirmed 2009
pandemic influenza A (H1N1) in both traditional and non-traditional household settings.
To access the full article in web-text (HTML) format, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5841a1.htm
To access a ready-to-print (PDF) version of this issue of
MMWR, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5841.pdf
Back to top |
|
|
18. |
MMWR article discusses recent progress made toward eradicating polio in
Nigeria
CDC published "Progress Toward Poliomyelitis
Eradication--Nigeria, January 2008-July 2009" in the October 23 issue of
MMWR. A summary made available to the press is reprinted
below in its entirety.
Despite increasing commitment by the government of Nigeria
to eliminating wild poliovirus transmission and some
indicators of progress, all three types of poliovirus are
still being transmitted and resulting in paralytic disease
among children; continued sustained commitment to polio
eradication activities is essential at national, state, and
local levels in Nigeria. Nigeria had the world's highest
burden of wild poliovirus (WPV) in 2008, with 798 (48
percent) of the 1,651 cases reported globally. During 2008-2009, Nigeria was the source of transmission of poliovirus
to thirteen neighboring countries. With increased activities
to interrupt WPV transmission during 2008, the number of
type 1 WPV dropped substantially in the first seven months
of 2009, as did the proportion of children who were reported
to have never received oral polio vaccine; however, type 3
WPV cases rose, and vaccine-derived poliovirus cases also
increased. With increased commitment of religious,
traditional, and community leaders, as well as increased
political oversight of polio vaccination activities with
better implementation, more children will be protected
against all three types of WPV in Nigeria.
To access the full article in web-text (HTML) format, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5841a3.htm
To access a ready-to-print (PDF) version of this issue of
MMWR, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5841.pdf
Back to top |
|
|
19. |
Phacilitate's North American Vaccine Forum scheduled for January 25-27 in
Washington, DC
The conference planning organization Phacilitate
has
scheduled a North American Vaccine Forum for January 25-27
in Washington, DC. For comprehensive information on the
event, go to:
http://www.phacilitate.co.uk/pages/washington_vac
Back to top |
|
|
|